-
SP600125 JNK Inhibitor: Applied Workflows
2026-09-17
SP600125 offers a practical way to test JNK-dependent phosphorylation, cytokine release, and cell-death phenotypes across cellular and inflammatory models. This guide combines compound-handling guidance with assay controls and a phosphosite-aware strategy inspired by recent chemoproteomic research.
-
Mubritinib Sensitizes NSCLC to Cisplatin
2026-09-17
The reference study shows that Mubritinib, also known as TAK 165, can strengthen cisplatin activity in non-small cell lung cancer by disrupting mitochondrial function, increasing reactive oxygen species, and promoting apoptosis. Its screening-to-xenograft design provides a mechanistic rationale for combining mitochondrial stress with DNA-damaging chemotherapy, while also defining important limits for translating the findings beyond the tested models.
-
CX-5461 RNA Polymerase I Inhibitor Workflow
2026-09-16
CX-5461 is an RNA polymerase I inhibitor for connecting ribosome biogenesis stress with DNA damage, mitotic catastrophe, autophagy, and senescence. This workflow emphasizes mechanism-linked assays, practical formulation controls, and combination studies relevant to solid tumor growth inhibition.
-
Crizotinib Hydrochloride in Gastric Assembloids
2026-09-15
Crizotinib hydrochloride provides a practical ALK, c-Met, and ROS1 pathway probe for patient-derived gastric cancer assembloids. Combining target-engagement measurements with matched tumor–stroma models can reveal response shifts that are invisible in organoid-only screens.
-
Latrunculin B for Actin Dynamics Workflows
2026-09-15
Latrunculin B offers a cell-permeable, short-duration way to test how actin filament assembly shapes morphology, trafficking, and entry phenotypes. Its serum-sensitive activity makes it especially useful for timed perturbations, matched vehicle controls, and mechanistic experiments where a negative result can be as informative as a positive one.
-
Wnt agonist 1: Assay Logic for Wnt–GPX4 Studies
2026-09-14
Wnt agonist 1, also known as BML-284, provides a controlled way to study canonical Wnt signaling and β-catenin–TCF transcription. This article develops an evidence-aware assay framework linking pathway activation with differentiation, metabolism, and chemoresistance without overstating what current data prove.
-
Mubritinib (TAK 165): Beyond HER2
2026-09-14
Mubritinib (TAK 165) is best understood not simply as a historical HER2 inhibitor, but as a mechanistically useful perturbation of mitochondrial complex I and oxidative phosphorylation. This thought-leadership analysis connects its activity in chemotherapy-resistant AML and KSHV-positive PEL with translational study design, formulation, pharmacology, and evidence discipline. It also explains why pH-mediated absorption research provides a valuable framework without justifying direct extrapolation to Mubritinib.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-13
A 2026 Advanced Science study uses single-cell profiling to identify SLC2A5-mediated fructose metabolism as a metabolic vulnerability in primary central nervous system lymphoma. Its findings connect glucose-poor, hypoxic tumor microenvironments with lymphoma-cell adaptation, macrophage support, and T-cell dysfunction, while functional perturbations provide a rationale for spatial and mechanistic validation.
-
Alpha-Ketoglutarate Workflows for Metabolic Research
2026-09-12
Use alpha-ketoglutarate as a controlled metabolic perturbation, an enzyme substrate, and a mechanistic probe for tumor–immune interactions. This workflow translates PDHA1 succinylation findings into practical metabolite, signaling, and macrophage antigen-presentation assays while separating exploratory conditions from established evidence.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-12
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical tumor suppressor replacement in bladder cancer. Its preclinical results link bladder-restricted expression with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced orthotopic tumor growth, while also defining important questions for formulation and translational validation.
-
Carbapenemase Gene Transmission in Enterobacter cloacae
2026-09-11
Chen et al. combined gene localization, susceptibility testing, plasmid conjugation, mobile-element analysis, and ERIC-PCR to characterize carbapenem-resistant Enterobacter cloacae across eight Guangdong teaching hospitals. The study identifies plasmid-associated blaNDM-1 as a major transferable resistance determinant and shows how horizontal gene transfer and clonal dissemination can coexist in hospital surveillance.
-
Carboplatin Assay Design: From DNA Damage to Decisions
2026-09-11
Carboplatin is a platinum-based DNA synthesis inhibitor with broad utility in preclinical oncology research. This guide presents an evidence-aware framework for selecting models, integrating orthogonal endpoints, and translating systematic-review insights into more informative cancer research assays.
-
Polygodial: Turning TRPA1 Signals into Translation
2026-09-10
Polygodial offers translational researchers a practical chemical handle for probing TRPA1-dependent sensory signaling. This article connects acute channel activation with calcium/NFAT biology, epithelial inflammatory outputs, assay design, and the limits of moving from mechanistic evidence to translational interpretation.
-
JNK-IN-7: A Translational Lens on JNK Signaling
2026-09-10
JNK-IN-7 offers a precise way to interrogate JNK1, JNK2, and JNK3 in inflammation- and infection-associated apoptosis models. By connecting covalent target engagement with phase-specific Candida krusei biology, this article provides a strategic framework for translational MAPK research, pathway validation, and assay design.
-
HotStart™ Universal 2X Green qPCR Master Mix for HCC
2026-09-09
Discover how HotStart™ Universal 2X Green qPCR Master Mix can support targeted validation of AI-derived hepatocellular carcinoma biomarkers. This article connects consensus prognostic modeling with assay design, specificity controls, and reproducible gene expression quantification.